Agreed: From 8-K 10/12/21....The company expects to provide a further clinical update in the first half of 2022. The Company is also in the process of launching and rebranding its new corporate website at www.rebus-corp.com. The company anticipates that subsequent to the reverse split it will be able to apply to list its Common Stock on the OTCQB tier of the OTC Markets Group, and eventually apply for a listing on a national exchange, in order to provide stockholders with more liquidity and allow the company more flexibility in accessing the capital markets.
I guess Silvestre is behind schedule on some of his ambitions noted in the merger documents. However, like most things these days he can blame covid as the root cause of the delays.
Be the change you want to see in the world!
Spread the love. Be the first to like this post!